S-2-硝基苯基-L-半胱氨酸 | 60115-45-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: S-2-硝基苯基-L-半胱氨酸
• 英文名称: S-(o-nitrophenyl)-L-cysteine
• 英文别名: (2R)-2-azaniumyl-3-(2-nitrophenyl)sulfanylpropanoate
• CAS: 60115-45-9
• 化学式: C₉H₁₀N₂O₄S
• 分子量: 242.255
• InChiKey: NDZOOTLIHLSPMZ-LURJTMIESA-N

物化性质

• 熔点：
  162-163 °C
• 沸点：
  431.3±45.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  134
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  S-2-硝基苯基-L-半胱氨酸 在 溶剂黄146 、 锌 作用下， 以83%的产率得到S-(2-aminophenyl)-L-cysteine
  参考文献：
  名称：

  S-Aryl-L-半胱氨酸 S,S-二氧化物：一类新型犬尿氨酸酶抑制剂的设计、合成和评价

  摘要：

  描述了 S-芳基-L-半胱氨酸 S，S-二氧化物的设计、制备和评估，这是一类新的来自荧光假单胞菌的犬尿氨酸酶的有效竞争抑制剂。这些化合物中最有效的 S-(2-氨基苯基)-L-半胱氨酸 S,S-二氧化物的 K i 值为 70 nM。当与犬尿氨酸酶结合时，这些类似物在 500 nm 处形成显着的可见吸收峰，分配给醌类中间体。用 S-(2-氨基苯基)-L-半胱氨酸 S,S-二氧化物滴定犬尿氨酸酶表明 1 mol 抑制剂与每个亚基中的 5'-磷酸吡哆醛结合

  DOI：

  10.1021/ja00057a007
• 作为产物：
  描述：

  N-acetyl-S-(2-nitro-phenyl)-L-cysteine 在 硫酸 作用下， 生成 S-2-硝基苯基-L-半胱氨酸
  参考文献：
  名称：

  S-Aryl cysteine S,S-dioxides as inhibitors of mammalian kynureninase

  摘要：

  A series of 2-amino-S-aryl cysteine S,S-dioxides have been synthesised and shown to inhibit kynureninase an important enzyme in the biosynthesis of the known excitotoxic moiety quinolinic acid. The most potent of these, 2-amino-5-methyl-S-phenyl cysteine S,S-dioxide 6d, inhibits interferon-gamma induced synthesis of quinolinic acid in human macrophages. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(97)10209-8

文献信息

• Synthesis and angiotensin converting enzyme inhibitory activity of 1,5-benzothiazepine and 1,5-benzoxazepine derivatives. I.
  作者：KATSUMI ITOH、MASAKUNI KORI、YOSHIYUKI INADA、KOHEI NISHIKAWA、YUTAKA KAWAMATSU、HIROSADA SUGIHARA

  DOI：10.1248/cpb.34.1128

  日期：——

  The design and synthesis of new structural types of angiotensin converting enzyme (ACE) inhibitors, (R)-3-amino-4-oxo-2, 3, 4, 5-tetrahydro-1, 5-benzothiazepine-5-acetic acids (7, 26, 33 and 37) and (S)-3-amino-4-oxo-2, 3, 4, 5-tetrahydro-1, 5-benzoxazepine-5-acetic acids (8 and 27), are described. A number of compounds in these series showed potent ACE inhibitory activity in vitro and in vivo. The structure-activity relationship is also discussed.

  新型血管紧张素转化酶（ACE）抑制剂的设计与合成，包括(R)-3-氨基-4-氧代-2, 3, 4, 5-四氢-1, 5-苯硫氮杂环-5-乙酸（7, 26, 33 和 37）以及(S)-3-氨基-4-氧代-2, 3, 4, 5-四氢-1, 5-苯氧氮杂环-5-乙酸（8 和 27），本文进行了描述。这些系列中的一些化合物在体外和体内显示出强烈的ACE抑制活性。同时讨论了结构-活性关系。
• Hetero-benzazepine derivatives and their pharmaceutical use
  申请人：Ciba-Geigy Corporation

  公开号：US04477464A1

  公开（公告）日：1984-10-16

  Disclosed are variously substituted 3-(carboxymethylamino)-(1,5-benzothiazepin-4-one, 1,5-benzoxazepin-4-one and 1,5-benzodiazepin-4-one)-5-alkanoic acids and derivatives as angiotensin-converting enzyme inhibitors and antihypertensive agents. Their synthesis, pharmaceutical compositions thereof, and methods of threatment utilizing such compounds are included.

  本发明涉及各种取代的3-（羧甲基氨基）-（1,5-苯并噻吩-4-酮，1,5-苯并噁唑-4-酮和1,5-苯并二氮杂-4-酮）-5-脂肪酸和衍生物作为血管紧张素转换酶抑制剂和降压剂。本发明还包括它们的合成，制药组合物以及利用这些化合物的治疗方法。
• Intermediates for the preparation of condensed seven-membered ring
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04739066A1

  公开（公告）日：1988-04-19

  Novel condensed seven-membered ring compounds of the formula: ##STR1## [wherein R.sup.1 and R.sup.2 are independently hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy, or both jointly form tri- or tetramethylene; R.sup.3 and R.sup.5 are independently hydrogen, lower alkyl or aralkyl; R.sup.4 is hydrogen or lower alkyl; R.sup.6 is a condensed or non-condensed hetero-alicyclic containing at least one atom of N, O and S as a ring-forming atom which may be substituted; A is an alkylene chain; n is 1 or 2] and salts thereof. These compounds exhibit inhibitory activity on angiotensin converting enzyme and so forth, and are of value as an agent for diagnosis, prevention and treatment of circulatory diseases, such as hypertension, cardiopathy and cerebral apoploxy.

  这是一种化合物的化学式：##STR1## [其中R.sup.1和R.sup.2分别为氢、卤素、三氟甲基、低碳基或低碳氧基，或共同形成三亚甲基或四亚甲基；R.sup.3和R.sup.5分别为氢、低碳基或芳基低碳基；R.sup.4为氢或低碳基；R.sup.6为含有至少一个N、O和S原子作为环形成原子的紧缩或非紧缩杂环，可以被取代；A是一个烷基链；n为1或2]和它们的盐。这些化合物表现出对血管紧张素转换酶等的抑制活性，并且作为诊断、预防和治疗循环系统疾病（如高血压、心脏病和脑中风）的药物具有价值。
• Condensed, seven-membered ring compounds and their use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04564612A1

  公开（公告）日：1986-01-14

  Novel condensed, seven-membered ring compounds of the formula: ##STR1## [wherein R.sup.1 and R.sup.2 each represent hydrogen, halogen, trifluoromethyl, lower alkyl or alkoxy, or both jointly form tri- or tetramethylene; R.sup.3 is hydrogen, lower alkyl or aralkyl; R.sup.4 is hydrogen or alkyl, aralkyl or cycloalkylalkyl which may be substituted; X is a group represented by the formula S(O).sub.n (where n is an integer of 0 to 2); Y is a carboxyl group which may be esterified or amidated; m is 1 or 2] and salts thereof. These compounds exhibit inhibitory activity on angiotensin converting enzyme and so forth, and are of value as an agent for diagnosis, prevention and treatment of hypertension.

  小说简化，式子为：##STR1##[其中R.sup.1和R.sup.2分别代表氢，卤素，三氟甲基，低烷基或烷氧基，或共同形成三元或四元亚甲基; R.sup.3是氢，低烷基或芳基烷基; R.sup.4是氢或烷基，芳基烷基或环烷基烷基，可以被取代; X是由式S(O).sub.n（其中n是0到2的整数）表示的基团; Y是羧基，可以酯化或酰胺化; m为1或2]及其盐。这些化合物表现出对血管紧张素转化酶等的抑制活性，因此在高血压的诊断、预防和治疗中具有价值。
• Condensed seven-membered ring compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04638000A1

  公开（公告）日：1987-01-20

  Novel condensed seven-membered ring compounds of the formula: ##STR1## [wherein R.sup.1 and R.sup.2 are independently hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy, or both jointly form tri- or tetramethylene; R.sup.3 and R.sup.5 are independently hydrogen, lower alkyl or aralkyl; R.sup.4 is hydrogen or lower alkyl; R.sup.6 is a condensed or non-condensed hetero-alicyclic containing at least one atom of N, O and S as a ring-forming atom which may be substituted; A is an alkylene chain; n is 1 or 2] and salts thereof. These compounds exhibit inhibitory activity on angiotensin converting enzyme and so forth, and are of value as an agent for diagnosis, prevention and treatment of circulatory diseases, such as hypertension, cardiopathy and cerebral apoploxy.

  这是一种化合物，其化学式为：##STR1## 其中R1和R2可以独立地是氢、卤素、三氟甲基、低碳基或低碳氧基，或者共同形成三元或四元亚甲基；R3和R5可以独立地是氢、低碳基或芳基低碳基；R4是氢或低碳基；R6是含有至少一个N、O和S原子作为环形成原子的紧缩或非紧缩杂环，可以被取代；A是一个烷基链；n为1或2。这些化合物表现出抑制血管紧张素转化酶等的活性，并且在诊断、预防和治疗循环系统疾病，如高血压、心脏病和脑卒中方面具有价值。